A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency

• Status: Terminated
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Male and female patients with severe AGHD.

• Hypopituitary patients must be on adequate hormone replacement therapy for at least 6 months.

Exclusion Criteria:

• AGHD patients with uncontrolled pituitary tumor growth.

• Tumors within 3 mm of the optic chiasm.

• Patients with diabetes mellitus.